Trial Profile
A Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-817399 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs BMS 817399 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 22 Oct 2009 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
- 15 Sep 2009 New trial record